The efficacy and safety of low-dose glucocorticoids combined withmethotrexate and hydroxychloroquine in the treatment of early rheumatoid arthritis: a randomized, double-blinded, controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900026116

Enrollment

Unknown

Registered

2019-09-22

Start date

2014-06-01

Completion date

Unknown

Last updated

2019-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

Experimental group:Prednisone+methotrexate+Hydrochloroquine

control group:placebo+methotrexate+Hydrochloroquine

Eligibility

Sex/Gender

All

Age

21 Years to 73 Years

Inclusion criteria

Inclusion criteria: 100 untreated patients, the course less than 12 months, in line with the 2009 American rheumatism association (ACR) and the European Union for resistance rheumatism (EULAR) proposed new RA classification standard ERA patients as the research object.

Exclusion criteria

Exclusion criteria: Patients who are prohibited from treating diseases such as diabetes and brittle bones with brittle fractures;In the first 2 months, there were serious infections (such as hepatitis, pneumonia and pyelonephritis); Pregnant women and lactating women; TB patients; Patients with tumors, multiple sclerosis, central nervous demyelination and congestive heart failure; Have other serious heart, liver, kidney and other important viscera and blood, endocrine system pathological changes and medical history.

Design outcomes

Primary

Measure	Time frame
DAS28;joint MRI;	—

Countries

China

Contacts

Public ContactHua Li

Central Hospital of Jinhua, Zhejiang

49124571@qq.com+86 13758992315

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026